Beta Bionics: Barclays initiates coverage with overweight rating and $30 target price
BBNX•Barclays initiated coverage of Beta Bionics with an overweight rating and a $30 target price.
Related News
Barclays raises QIAGEN to overweight from equal-weight, lifts target price to $55 from $40
QGEN•
AI companies run virtual drug trials, aim to improve success of human studies
BIIB•
Cencora: Leerink Partners raises target price to $388 from $380
COR•
Ocean Power Technologies names Victoria Hay interim CFO after Robert Powers exit
OPTT•